Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Age-Related Macular Degeneration

Age-Related Macular Degeneration

Subtypes of Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration 9 Cystoid Macular Edema 1 Geographic Atrophy 1 Irvine-Gass Syndrome 1 Macular edema 1

18 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Age-Related Macular Degeneration

79 trials tracked for Age-Related Macular Degeneration: 23 in phase 3 or 4 and 11 with published results. The most-cited published study has 839 citations.

79Trials tracked
23Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 10 Phase 3 13 Phase 2 34 Phase 1 6 Other / NA 16
  1. Phase 4 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed · 839 cited
  2. Phase 4 Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) Completed · 291 cited
  3. Phase 4 A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients Completed · 137 cited
  4. Phase 3 Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD Completed · 137 cited
  5. Phase 4 Study for Recalcitrant Age Related Macular Degeneration Completed · 86 cited
  6. Phase 3 A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) Completed · 81 cited
Show 44 more trials
  1. Phase 3 Phase 2/3 Study of ALK-001 in Geographic Atrophy Completed · 46 cited
  2. Phase 4 Study EvAluating Genotypes While Using Lucentis 2 Completed · 38 cited
  3. Phase 4 An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Completed · 19 cited
  4. Phase 4 Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration Completed · 12 cited
  5. Phase 3 Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD Completed · 4 cited
  6. Phase 4 Head to Head Study of Anti-VEGF Treatment. Completed
  7. Phase 4 Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium Completed
  8. Phase 4 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed
  9. Phase 3 Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Completed
  10. Phase 3 Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Completed
  11. Phase 3 A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) Completed
  12. Phase 3 Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial Completed
  13. Phase 3 Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) Completed
  14. Phase 3 Low Vision Depression Prevention Trial for Age Related Macular Degeneration Completed
  15. Phase 3 Improving Function in Age-Related Macular Degeneration Completed
  16. Phase 3 Age-Related Eye Disease Study 2 (AREDS2) Completed
  17. Phase 3 SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Completed
  18. Phase 2 Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) Completed
  19. Phase 2 ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA Completed
  20. Phase 2 INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Completed
  21. Phase 2 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) Completed
  22. Phase 2 Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration Completed
  23. Phase 2 Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD) Completed
  24. Phase 2 Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) Completed
  25. Phase 2 Alpha Lipoic Acid in Geographic Atrophy Completed
  26. Phase 2 Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD) Completed
  27. Phase 2 Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD Completed
  28. Phase 2 A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration Completed
  29. Phase 2 Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD Completed
  30. Phase 2 Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Completed
  31. Phase 2 OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration Completed
  32. Phase 2 IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD Completed
  33. Phase 2 Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration Completed
  34. Phase 2 Dose Ranging Study of Carbidopa-levodopa Completed
  35. Phase 2 RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration Completed
  36. Phase 2 A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) Completed
  37. Phase 2 Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF Completed
  38. Phase 2 Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study Completed
  39. Phase 2 Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration Completed
  40. Phase 2 The Moran AMD Genetic Testing Assessment Study Completed
  41. Phase 2 The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot Completed
  42. Phase 2 Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects Completed
  43. Phase 2 Sirolimus for Advanced Age-Related Macular Degeneration Completed
  44. Phase 2 Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT) Completed

Showing the 50 most-cited and recently-updated of 79 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR
Ophthalmology FDA Approval
FDA Approves Pavblu (aflibercept) for Neovascular AMD, RVO, DME, and DR FDA approves Pavblu to treat several eye conditions that cause vision loss.
The FDA approved Pavblu (aflibercept) for neovascular AMD, macular edema following RVO, DME, and DR. It is a VEGF inhibitor administered by …
The FDA approved Pavblu (aflibercept) for wet age-related macular degeneration, macular edema, diabetic macular edema, and diabetic retinopa…
FDA May 5, 2026
Obstructive Sleep Apnea Associated with Higher Odds of Age-Related Macular Degeneration
Ophthalmology Meta-analysis
Obstructive Sleep Apnea Associated with Higher Odds of Age-Related Macular Degeneration Large study links obstructive sleep apnea to higher risk of age-related macular degeneration
A systematic review and meta-analysis of 3,536,314 adults found that obstructive sleep apnea (OSA) was associated with higher odds of age-re…
A massive analysis of over 3.5 million people suggests obstructive sleep apnea is linked to a higher risk of age-related macular degeneratio…
May 1, 2026
Systematic review and meta-analysis shows aflibercept biosimilars match reference drug efficacy and safety in AMD and DME
Ophthalmology Meta-analysis
Systematic review and meta-analysis shows aflibercept biosimilars match reference drug efficacy and safety in AMD and DME Aflibercept biosimilars match the original drug for eye disease treatment
This systematic review and meta-analysis evaluated aflibercept biosimilars versus reference aflibercept for neovascular age-related macular …
A large review of 4064 patients found that aflibercept biosimilars work just as well as the original drug for two common eye conditions.
May 1, 2026
AI-based fluid volume quantification predicts visual acuity in neovascular AMD better than CST
Ophthalmology RCT
AI-based fluid volume quantification predicts visual acuity in neovascular AMD better than CST AI fluid measurements better predict vision loss than thickness in AMD
This randomized phase III trial in 290 eyes with neovascular AMD found that AI-based quantification of intraretinal and subretinal fluid vol…
AI-based fluid volume tracking explains more vision changes than standard thickness measurements in macular degeneration patients.
May 1, 2026
Systematic review finds radiotherapy combined with anti-VEGF therapy increases risk of vision loss compared to anti-VEGF monotherapy in nAMD
Ophthalmology Meta-analysis
Systematic review finds radiotherapy combined with anti-VEGF therapy increases risk of vision loss compared to anti-VEGF monotherapy in nAMD Radiotherapy plus anti-VEGF therapy increases vision loss risk for nAMD
This systematic review and meta-analysis evaluated radiotherapy combined with anti-VEGF therapy versus anti-VEGF monotherapy for neovascular…
Adding radiotherapy to anti-VEGF treatment for wet macular degeneration was linked to a higher risk of vision loss compared to anti-VEGF alo…
May 1, 2026
Systematic review and meta-analysis finds no significant association between diabetic retinopathy and age-related macular degeneration
Diabetes & Endocrinology Meta-analysis
Systematic review and meta-analysis finds no significant association between diabetic retinopathy and age-related macular degeneration Diabetic retinopathy and age-related macular degeneration show no significant link
This systematic review and meta-analysis evaluates the association between diabetic retinopathy and age-related macular degeneration.
A meta-analysis found no significant relationship between diabetic retinopathy and age-related macular degeneration, though existing data ha…
May 1, 2026
Avacincaptad pegol reduces geographic atrophy growth compared to sham in Age-Related Macular Degeneration patients
Drug Pipeline RCT
Avacincaptad pegol reduces geographic atrophy growth compared to sham in Age-Related Macular Degeneration patients This Eye Injection Slows Blindness for Two Years Straight
This phase 3, randomized, sham-controlled study evaluated avacincaptad pegol in patients with non-center point-involving geographic atrophy.
For patients with a leading cause of blindness, this treatment offers lasting protection without new side effects.
Apr 24, 2026
Narrative review associates melatonin use with delayed age-related macular degeneration in Americans over 40
Ophthalmology Sys. Review
Narrative review associates melatonin use with delayed age-related macular degeneration in Americans over 40 Melatonin May Slow Vision Loss in Aging Eyes
This narrative review examines the association between melatonin use and delayed age-related macular degeneration (AMD) in Americans over th…
Melatonin, the sleep hormone, may slow vision loss in aging eyes by fighting the oxidative stress that damages cells in age-related macular …
Frontiers Apr 15, 2026
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation
Ophthalmology
Proteomic profiling in anti-VEGF-treated AMD patients reveals VEGF-independent immune pathway activation Why Immune Cells Keep Damaging Your Eyes
This observational study analyzed vitreous proteomic profiles in eight patients with neovascular AMD receiving anti-VEGF therapy compared to…
Standard eye drops for AMD stop one problem, but a second, hidden immune attack is still hurting your vision.
medRxiv Apr 14, 2026
Smoking, aging, and CRP levels associated with cataract and AMD comorbidity risk in 640 participants
Primary Care & Family Medicine Cohort
Smoking, aging, and CRP levels associated with cataract and AMD comorbidity risk in 640 participants Study links smoking and aging to higher risk of cataract and macular degeneration
This retrospective case-control study evaluated risk factors for cataract and age-related macular degeneration comorbidity in 640 participan…
Smoking combined with aging exponentially raises the risk of developing both cataracts and macular degeneration in people over 75.
Frontiers Apr 13, 2026
Retrospective study links systemic BP control to better visual outcomes with conbercept for RVO-related macular edema
Dermatology Cohort
Retrospective study links systemic BP control to better visual outcomes with conbercept for RVO-related macular edema Your Blood Pressure May Decide How Well Eye Injections Work
A retrospective cohort study of 76 hypertensive patients with macular edema secondary to retinal vein occlusion found that those with contro…
If you need eye injections for fluid swelling behind the retina, keeping your blood pressure in check could decide how much vision you get b…
Frontiers Apr 13, 2026
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO
Ophthalmology FDA Approval
FDA Approves Eylea HD (aflibercept) for nAMD, DME, Diabetic Retinopathy, and Macular Edema Following RVO FDA approves a new, higher-dose version of the eye medicine Eylea
The FDA has approved Eylea HD, a VEGF inhibitor, for the treatment of neovascular age-related macular degeneration, diabetic macular edema, …
FDA approves higher-dose Eylea to treat four eye conditions that damage the retina and threaten vision, potentially reducing how often patie…
FDA Apr 7, 2026

Questions about Age-Related Macular Degeneration

How do smoking and aging affect the risk of having both cataracts and Age-Related Macular Degeneration?

Smoking and aging strongly increase the risk of having both cataracts and age-related macular degeneration, with a synergistic effect in people over 75.

Full answer →
Can machine learning models predict if my early Age-Related Macular Degeneration will get worse?

Yes, machine learning models can predict progression from early to late AMD with moderate accuracy, using imaging and clinical data.

Full answer →
Is there a link between diabetic retinopathy and getting Age-Related Macular Degeneration?

Current research shows no significant link between diabetic retinopathy and age-related macular degeneration, despite both conditions sharing some similar underlying mechanisms.

Full answer →
Does having obstructive sleep apnea increase my risk for Age-Related Macular Degeneration?

Yes, obstructive sleep apnea may increase your risk for age-related macular degeneration, especially the neovascular (wet) form, though the evidence is mixed.

Full answer →

All Age-Related Macular Degeneration Articles